<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162250</url>
  </required_header>
  <id_info>
    <org_study_id>GV39131</org_study_id>
    <secondary_id>2016-001880-35</secondary_id>
    <nct_id>NCT03162250</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics</brief_title>
  <official_title>A Phase IB, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib, randomized double-blind, placebo-controlled multiple-ascending dose study
      to investigate the safety, tolerability, and pharmacokinetics of multiple doses of DSTA4637S
      when given in addition to anti-staphylococcal SOC antibiotics to participants with
      methicillin-resistant staphylococcus aureus (MRSA) and methicillin-sensitive staphylococcus
      aureus (MSSA) bacteremia requiring at least 4 weeks of anti-staphylococcal SOC antibiotics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2017</start_date>
  <completion_date type="Anticipated">February 4, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Antibody-Conjugated 4-Dimethylamino Piperidino-Hydroxybenzoxazino Rifamycin (dmDNA31) measured by Plasma</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of DSTA4637S Total Antibody measured by Serum</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Unconjugated dmDNA31 measured by Plasma</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to DSTA4637S</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>DSTA4637S low dose level + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSTA4637S low dose level intravenous (IV) infusion will be administered on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSTA4637S intermediate dose level+ SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSTA4637S intermediate dose level IV infusion will be administered on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSTA4637S high dose level+ SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSTA4637S high dose level IV infusion will be administered on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to DSTA4637S IV infusion will be administered on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSTA4637S</intervention_name>
    <description>DSTA4637S will be administered as an IV infusion at 3 dose levels.</description>
    <arm_group_label>DSTA4637S low dose level + SOC</arm_group_label>
    <arm_group_label>DSTA4637S intermediate dose level+ SOC</arm_group_label>
    <arm_group_label>DSTA4637S high dose level+ SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to DSTA4637S IV infusion will be administered as specified.</description>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.</description>
    <arm_group_label>DSTA4637S low dose level + SOC</arm_group_label>
    <arm_group_label>DSTA4637S intermediate dose level+ SOC</arm_group_label>
    <arm_group_label>DSTA4637S high dose level+ SOC</arm_group_label>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index greater than or equal (&gt;/=) 18 to less than or equal to (&lt;/=) 32
             kg/m^2

          -  At randomization, participants must have &gt;/=1 blood culture or molecular diagnostic
             that is positive for Staphylococcal aureus (S. aureus) collected in the previous 120
             hours

          -  In the investigator's judgment, an expected treatment duration for S. aureus infection
             with anti-staphylococcal SOC antibiotics &gt;/= 4 weeks

          -  Use of contraceptive measures for men and women

        Exclusion Criteria:

          -  The presence of an intravascular catheter that is not planned to be removed within 48
             hours of study randomization

          -  S. aureus bacteremia associated with a removable or non-removable source of infection
             at the time a positive blood culture was drawn

          -  Known rifampicin-resistant S. aureus

          -  Anticipated receipt of a rifamycin class antibiotic from Day 1 to study
             completion/discontinuation

          -  In the investigator's judgment, a high likelihood of cardiac surgery or death within 3
             days after randomization

          -  A known history of active hepatitis B and C

          -  Creatinine clearance &lt;/=30 milliliters per minute (mL/min) (end stage renal disease)
             or on hemodialysis

          -  Any participant with known HIV infection not on appropriate SOC anti-retroviral
             therapy

          -  Polymicrobial bacteremia

          -  Any participant with known or suspected, active tuberculosis

          -  Participants with significant immune suppression

          -  Alanine transaminase (ALT) &gt;/=5 times the upper limit of normal (ULN) at any time from
             screening up to randomization

          -  Aspartate transaminase (AST) or ALT &gt;/=3 times the ULN with bilirubin &gt;/=2 Ã— ULN at
             any time from screening up to randomization

          -  History of anaphylactic or hypersensitivity drug reaction, unless approved by the
             investigator and sponsor

          -  History or presence of an abnormal electrocardiogram (ECG) that is clinically
             significant in the investigator's opinion

          -  Exposure to any biological therapy or investigational biological agent within 90 days
             prior to the screening evaluation or have received any other investigational treatment
             30 days prior to the screening evaluation

          -  Any history of hypersensitivity or allergy to rifampin or other rifamycin analogs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reference Study ID Number: GV39131 www.roche.com/abo</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Gyeongsangnam-do</city>
        <zip>52727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

